Martin Hagedorn
Overview
Explore the profile of Martin Hagedorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hillmer D, Merhi R, Boniface K, Taieb A, Barnetche T, Seneschal J, et al.
J Invest Dermatol
. 2023 Aug;
144(2):351-357.e4.
PMID: 37586608
Vitiligo is the most common depigmenting skin disorder. Given the ongoing development of new targeted therapies, it has become important to evaluate adequately the surface area involved. Assessment of vitiligo...
2.
Rahal F, Capdevielle C, Rousseau B, Izotte J, Dupuy J, Cappellen D, et al.
Neurooncol Adv
. 2022 Mar;
4(1):vdac018.
PMID: 35300150
Background: Diffuse Midline Glioma, H3K27M-mutant (DMG) is a rare, highly aggressive pediatric tumor affecting the brainstem, and is one of the deadliest cancers. Currently available treatment options such as chemotherapy...
3.
Capdevielle C, Hagedorn M
Aging (Albany NY)
. 2021 Oct;
13(20):23440-23441.
PMID: 34705668
No abstract available.
4.
Capdevielle C, Desplat A, Charpentier J, Sagliocco F, Thiebaud P, Theze N, et al.
Neuro Oncol
. 2019 Nov;
22(4):550-562.
PMID: 31711240
Background: Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and...
5.
Hagedorn M, Liebich L, Bogershausen A, Massing U, Hoffmann S, Mende S, et al.
Int J Pharm
. 2019 May;
565:187-198.
PMID: 31063837
Various wet ball nanomilling-screening tools for poorly soluble APIs are available which differ in their milling principle, batch size and number of samples. Here, the transferability of results from screening...
6.
Indersie E, Hooks K, Capdevielle C, Fabre M, Dugot-Senant N, Desplat A, et al.
Oncotarget
. 2018 Apr;
9(22):16149-16162.
PMID: 29662633
Hepatoblastoma (HBL) is a pediatric liver cancer with defined molecular alterations driving its progression. Here, we describe an animal model for HBL on the chick chorioallantoic membrane (CAM), which recapitulates...
7.
Indersie E, Lesjean S, Hooks K, Sagliocco F, Ernault T, Cairo S, et al.
Hepatol Commun
. 2018 Feb;
1(2):168-183.
PMID: 29404451
Hepatoblastoma (HBL) is the most common pediatric liver cancer. In this malignant neoplasm, beta-catenin protein accumulates and increases Wnt signaling due to recurrent activating mutations in the catenin-beta 1 ()...
8.
Hooks K, Audoux J, Fazli H, Lesjean S, Ernault T, Dugot-Senant N, et al.
Hepatology
. 2017 Nov;
68(1):89-102.
PMID: 29152775
Conclusion: The highly proliferating C2A subtype is characterized by topoisomerase 2-alpha gene up-regulation and FA pathway activation, and the HB therapeutic arsenal could include bortezomib for the treatment of patients...
9.
Hagedorn M, Bogershausen A, Rischer M, Schubert R, Massing U
Int J Pharm
. 2017 Jul;
530(1-2):79-88.
PMID: 28733242
The development of nanosuspensions of poorly soluble APIs takes a lot of time and high amount of active material is needed. In this publication the use of dual centrifugation (DC)...
10.
Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks K, Ghousein A, et al.
Oncotarget
. 2017 May;
8(25):41211-41226.
PMID: 28476031
Glypican-3 (GPC3) is an oncogene, frequently upregulated in liver malignancies such as hepatocellular carcinoma (HCC) and hepatoblastoma and constitutes a potential molecular target for therapy in liver cancer. Using a...